Physician profile
Ashok Kumar Tripuraneni
NPI 1336190610
$6,743.06
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,865 · 2020: $953 · 2021: $1,596 · 2022: $1,971 · 2023: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $276 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.55 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,718.79 | 2019-2023 | Kyprolis, Blincyto |
| Janssen Biotech, INC. | $637.92 | 2019-2023 | Imbruvica |
| Incyte Corporation | $497.58 | 2019-2023 | Jakafi, Pemazyre, Monjuvi |
| Novartis Pharmaceuticals Corporation | $315.13 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $259.69 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $248.00 | 2019-2022 | |
| Pfizer INC. | $235.36 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $216.03 | 2019-2022 | |
| Amag Pharmaceuticals, INC. | $207.69 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $205.87 | 2019-2022 | |
| Celgene Corporation | $185.26 | 2019-2022 | |
| Coherus Oncology, INC. | $175.21 | 2020-2022 | |
| Genzyme Corporation | $166.68 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $160.13 | 2021-2023 | |
| Actelion Pharmaceuticals US, INC. | $125.00 | 2019 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashok Tripuraneni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.